Cyanidin-3-o-glucoside (C3G) inhibits vascular leakage regulated by microglial activation in early diabetic retinopathy and neovascularization in advanced diabetic retinopathy

References

• Hernández C, Simó-Servat O, Simó R. Simó-Servat O and Simó R. Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine. 2014;46:209–214.
   PubMed Web of Science ®Google Scholar
• Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 2011;89:405–411.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Treatment of diabetic retinopathy: recent advances and unresolved challenges. World J Diabetes. 2016;7:333–341.
   PubMed Web of Science ®Google Scholar
• Singh RP, Elman MJ, Singh SK, et al. Advances in the treatment of diabetic retinopathy. J Diabetes Complications. 2019;33:107417.
   PubMed Web of Science ®Google Scholar
• Pearce E, Sivaprasad S. A review of advancements and evidence gaps in diabetic retinopathy screening models. Clin Ophthalmol. 2020;14:3285–3296.
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, Joglekar MV, Hardikar AA, et al. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015;12:159–195.
   PubMedGoogle Scholar
• Wilkinson CP, Ferris FL 3rd, Klein RE, et al.; Global Diabetic Retinopathy Project G. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–1682.
   PubMed Web of Science ®Google Scholar
• Jhingan M, Goud A, Peguda HK, et al. Subthreshold microsecond laser for proliferative diabetic retinopathy: a randomized pilot study. Clin Ophthalmol. 2018;12:141–145.
   PubMed Web of Science ®Google Scholar
• Royle P, Mistry H, Auguste P, et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technol Assess. 2015;19:v–xxviii, 1–247.
   PubMed Web of Science ®Google Scholar
• Mistry H, Auguste P, Lois N, et al. Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early? BMJ Open Ophthalmol. 2017;2:e000021.
   PubMed Web of Science ®Google Scholar
• Madonna R, Balistreri CR, Yj G, et al. Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches. Vascul Pharmacol. 2017;90:1–7.
   PubMed Web of Science ®Google Scholar
• Wu JH, Li YN, Chen AQ, et al. Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med. 2020;12:e10154.
   PubMed Web of Science ®Google Scholar
• Min SW, Sn R, Dh K. Anti-inflammatory effects of black rice, cyanidin-3-O-beta-D-glycoside, and its metabolites, cyanidin and protocatechuic acid. Int Immunopharmacol. 2010;10:959–966.
   PubMed Web of Science ®Google Scholar
• Sorrenti V, Vanella L, Acquaviva R, et al. Cyanidin induces apoptosis and differentiation in prostate cancer cells. Int J Oncol. 2015;47:1303–1310.
   PubMed Web of Science ®Google Scholar
• Cho E, Chung EY, Jang HY, et al. Anti-cancer effect of Cyanidin-3-glucoside from Mulberry via Caspase-3 Cleavage and DNA Fragmentation in vitro and in vivo. Anticancer Agents Med Chem. 2017;17:1519–1525.
   PubMed Web of Science ®Google Scholar
• Wen L, Jiang X, Sun J, et al. Cyanidin-3-O-glucoside promotes the biosynthesis of progesterone through the protection of mitochondrial function in Pb-exposed rat leydig cells. Food Chem Toxicol. 2018;112:427–434.
   PubMed Web of Science ®Google Scholar
• Song XL, Li MJ, Liu Q, et al. Cyanidin-3-O-glucoside protects lens epithelial cells against high glucose-induced apoptosis and prevents cataract formation via suppressing NF-κB activation and Cox-2 expression. J Agric Food Chem. 2020;68:8286–8294.
   PubMed Web of Science ®Google Scholar
• Li W, Chen S, Zhou G, et al. Potential role of cyanidin 3-glucoside (C3G) in diabetic cardiomyopathy in diabetic rats: an in vivo approach. Saudi J Biol Sci. 2018;25:500–506.
   PubMed Web of Science ®Google Scholar
• Ma X, Ning S. Cyanidin-3-glucoside attenuates the angiogenesis of breast cancer via inhibiting STAT3/VEGF pathway. Phytother Res. 2019;33:81–89.
   PubMed Web of Science ®Google Scholar
• Martín-Granado V, Ortiz-Rivero S, Carmona R, et al. C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis. Oncotarget. 2017;8:110994–111011.
   PubMedGoogle Scholar
• Yan X, Wu L, Li B, et al. Cyanidin-3-O-glucoside attenuates acute lung injury in sepsis rats. J Surg Res. 2015;199:592–600.
   PubMed Web of Science ®Google Scholar
• Long L, Li Y, Yu S, et al. Scutellarin prevents angiogenesis in diabetic retinopathy by downregulating VEGF/ERK/FAK/Src pathway signaling. J Diabetes Res. 2019;2019:4875421.
   PubMed Web of Science ®Google Scholar
• Petrovic D. Candidate genes for proliferative diabetic retinopathy. Biomed Res Int. 2013;2013:540416.
   PubMed Web of Science ®Google Scholar
• Kaewmool C, Udomruk S, Phitak T, et al. Cyanidin-3-O-glucoside protects PC12 cells against neuronal apoptosis mediated by LPS-stimulated BV2 microglial activation. Neurotox Res. 2020;37:111–125.
   PubMed Web of Science ®Google Scholar
• Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363–365.
   PubMed Web of Science ®Google Scholar
• Gustavsson C, Cd A, Agardh E. Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol. 2013;91:445–452.
   PubMed Web of Science ®Google Scholar
• Koleva-Georgieva DN, Np S, Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 2011;53:44–50.
   PubMedGoogle Scholar
• Feng S, Yu H, Yu Y, et al. Levels of inflammatory cytokines IL-1β, IL-6, IL-8, IL-17A, and TNF-α in aqueous humour of patients with diabetic retinopathy. J Diabetes Res. 2018;2018:8546423.
   PubMed Web of Science ®Google Scholar
• Wu H, Hwang DK, Song X, et al. Association between aqueous cytokines and diabetic retinopathy stage. J Ophthalmol. 2017;2017:9402198.
   PubMed Web of Science ®Google Scholar
• Liu X, Ye F, Xiong H, et al. IL-1β induces IL-6 production in retinal Müller cells predominantly through the activation of p38 MAPK/NF-κB signaling pathway. Exp Cell Res. 2015;331:223–231.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang Y, Jin W, et al. Catechin weakens diabetic retinopathy by inhibiting the expression of NF-κB signaling pathway-mediated inflammatory factors. Ann Clin Lab Sci. 2018;48:594–600.
   PubMed Web of Science ®Google Scholar
• Yang Q, Li S, Zhou Z, et al. HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-κB and NLRP3 inflammasome pathway. Gen Physiol Biophys. 2020;39:169–177.
   PubMed Web of Science ®Google Scholar
• Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018;19:110.
   PubMed Web of Science ®Google Scholar
• Scholz R, Caramoy A, Bhuckory MB, et al. Targeting translocator protein (18 kDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration. J Neuroinflammation. 2015;12:201.
   PubMed Web of Science ®Google Scholar
• Tambuyzer BR, Ponsaerts P, Ej N. Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol. 2009;85:352–370.
   PubMed Web of Science ®Google Scholar
• Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312–318.
   PubMed Web of Science ®Google Scholar
• Shao J, Yao Y. Transthyretin represses neovascularization in diabetic retinopathy. Mol Vis. 2016;22:1188–1197.
   PubMed Web of Science ®Google Scholar
• Liu H, Lessieur EM, Saadane A, et al. Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy. Diabetologia. 2019;62:2365–2374.
   PubMed Web of Science ®Google Scholar
• Singh A, Stewart JM. Pathophysiology of diabetic macular edema. Int Ophthalmol Clin. 2009;49:1–11.
   PubMedGoogle Scholar
• Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19:442–455.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2009;148:883–889.
   PubMed Web of Science ®Google Scholar
• Jankowska-Konsur A, Kobierzycki C, Grzegrzolka J, et al. Expression of CD31 in mycosis fungoides. Anticancer Res. 2016;36:4575–4582.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang S, Wan T, et al. Cyanidin-3-O-β-glucoside inactivates NLRP3 inflammasome and alleviates alcoholic steatohepatitis via SirT1/NF-κB signaling pathway. Free Radic Biol Med. 2020;160:334–341.
   PubMed Web of Science ®Google Scholar
• Lian W, Chen W. Cyanidin-3-O-glucoside improves colonic motility during severe acute pancreatitis by inhibiting the H(2) S-regulatedAMPK/mTOR pathway. Drug Des Devel Ther. 2020;14:3385–3391.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang M, Wang Z, et al. Cyanidin-3-O-glucoside attenuates endothelial cell dysfunction by modulating miR-204-5p/SIRT1-mediated inflammation and apoptosis. Biofactors. 2020;46:803–812.
   PubMed Web of Science ®Google Scholar